Who are sodium bicarbonate 8.4%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): trisodium citrate, Experimental - 4% Sodium Bicarbonate, Intravenous sodium bicarbonate, Sodium Bicarbonate 7.5% Injection, Intensive treatment with sodium bicarbonate, Sodium Bicarbonate Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sodium-bicarbonate-8-4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

sodium bicarbonate 8.4% — Competitive Intelligence Brief

sodium bicarbonate 8.4% (sodium bicarbonate 8.4%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkalinizing agent. Area: Critical Care / Emergency Medicine.

marketed Alkalinizing agent Critical Care / Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

sodium bicarbonate 8.4% (sodium bicarbonate 8.4%) — University of Baghdad. Sodium bicarbonate acts as a systemic alkalinizing agent that increases blood pH and bicarbonate concentration to counteract metabolic acidosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
sodium bicarbonate 8.4% TARGET	sodium bicarbonate 8.4%	University of Baghdad	marketed	Alkalinizing agent
trisodium citrate	trisodium citrate	Onze Lieve Vrouwe Gasthuis	marketed	Anticoagulant / Alkalinizing agent	Ionized calcium (Ca2+)
Experimental - 4% Sodium Bicarbonate	Experimental - 4% Sodium Bicarbonate	Baptist Health South Florida	marketed	Antacid / Alkalinizing agent
Intravenous sodium bicarbonate	Intravenous sodium bicarbonate	The Western Pennsylvania Hospital	marketed	Alkalinizing agent
Sodium Bicarbonate 7.5% Injection	Sodium Bicarbonate 7.5% Injection	Hospital General "Dr. Miguel Silva" de Morelia	marketed	Alkalinizing agent
Intensive treatment with sodium bicarbonate	Intensive treatment with sodium bicarbonate	University of Roma La Sapienza	marketed	pH modulator / alkalinizing agent
Sodium Bicarbonate Solution	Sodium Bicarbonate Solution	VA Greater Los Angeles Healthcare System	marketed	Alkalinizing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkalinizing agent class)

Hospital General "Dr. Miguel Silva" de Morelia · 1 drug in this class
Jennifer Gassman, PhD · 1 drug in this class
The Western Pennsylvania Hospital · 1 drug in this class
University of Baghdad · 1 drug in this class
VA Greater Los Angeles Healthcare System · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sodium bicarbonate 8.4% — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-bicarbonate-8-4. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab